ORGO at a glance
Organogenesis Holdings Inc. (ORGO, SEC CIK 1661181) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as April 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Organogenesis Holdings Inc. (ORGO) reported revenue of $564.2 million (up 17.0% from FY2024) and net income of $37.0 million. Diluted EPS was $0.15.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Organogenesis Holdings Inc. (ORGO) shares worth $94.9 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Driscoll Michael Joseph on March 9, 2026 of 10,000 shares at $2.67 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $564.2M
- +17.0% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $94.9M · +0 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Total revenue $43.755M, down 57% YoY from $101.005M
- Gross margin 43.7% vs 72.4% YoY; operating loss $50.992M vs $12.576M
- Advanced Wound Care revenue $36.146M, down 61%; Surgical & Sports Medicine $6.659M, down 18%
- Six-month operating cash use $10.526M vs $52.808M; cash and equivalents $46.1M at June 30
- CMS reimbursement changes and market disruption drove declines; Dermagraft relaunch timing no longer projected
Risk Factors
- No newly added, updated, regulatory, operational, competitive, market, or financial risks identifiable from supplied text
AI summary of the ORGO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Fiscal Q2 2026 results covered quarter ended June 30, 2026
- Earnings details provided in Exhibit 99.1 press release
Item EX-99.1: Item EX-99.1
- Q2 revenue $42.8M, down 58%, with Advanced Wound Care falling 61% to $36.1M
- Gross margin collapsed to 45% from 73%, while net loss widened to $96.3M from $9.4M
Item 1.01: Entry into a Material Definitive Agreement
- $75 million ATM facility enables incremental Class A share issuance through BTIG and Citizens
- Potential equity dilution and selling pressure, depending on issuance volume and market prices
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Garrett Lustig re-elected to Organogenesis’ board through the next annual meeting
- Series A Convertible Preferred Stockholders approved the election by written consent
Item 5.07: Submission of Matters to a Vote of Security Holders
- All nine director nominees elected, with Jon Giacomin and Glenn H. Nussdorf receiving the highest withheld votes
- Executive compensation approved advisory, with 72,516,011 votes for and 12,722,258 against
AI summaries of ORGO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ORGO
Don't miss the next ORGO filing
- Alerts as it files. A push when ORGO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ORGO, by share count.
- Ask anything. An AI agent that reads every ORGO filing and answers with sources.
ORGO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Driscoll Michael Joseph | Buy | Mar 9, 2026 | 10,000 | $2.67 |
| Leibowitz Arthur S | Buy | Mar 9, 2026 | 5,000 | $2.68 |
| Cavorsi Robert | F | Feb 18, 2026 | 5,432 | $3.84 |
| Francisco David | A | Feb 18, 2026 | 111,358 | - |
| Cavorsi Robert | A | Feb 18, 2026 | 93,750 | - |
| Cavorsi Robert | A | Feb 18, 2026 | 16,290 | - |
| Francisco David | A | Feb 18, 2026 | 195,312 | - |
| Duraibabu Prathyusha | A | Feb 18, 2026 | 48,828 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $482.0M | $564.2M |
| Gross Profit | - | $366.3M | - |
| Operating Income | - | -$1.3M | $44.7M |
| Net Income | - | $861K | $37.0M |
| Gross Margin | - | 76.0% | - |
| Op. Margin | - | -0.3% | 7.9% |
| Net Margin | - | 0.2% | 6.6% |
| Balance Sheet | |||
| Total Assets | $460.0M | $497.9M | $598.7M |
| Equity | $278.7M | $262.9M | $300.1M |
| ROE | - | 0.3% | 12.3% |
| Per Share | |||
| EPS | - | $-0.01 | $0.15 |
| Cash Flow | |||
| Operating CF | - | $14.2M | -$10.3M |
| CapEx | $24.4M | $10.0M | $14.2M |
Source: XBRL data in Organogenesis Holdings Inc. (ORGO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ORGO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $94.9M |
| Q1 2026 | 26 | $78.2M |
| Q4 2025 | 25 | $174.7M |
| Q3 2025 | 26 | $132.6M |
| Q2 2025 | 26 | $118.6M |
| Q1 2025 | 23 | $127.4M |
| Q4 2024 | 17 | $44.5M |
| Q3 2024 | 15 | $28.8M |
- BlackRock+2.35M (+48%)
- AQR Capital Management+2.13M (+242%)
- D.E. Shaw & Co+590.3K (+26%)
- Goldman Sachs Group+367.0K (+71%)
- Citadel Advisors LLC+323.7K (+59%)
- FMR LLC (Fidelity)−160.2K (-43%)
- Prudential Financial−135.4K (-93%)
- Renaissance Technologies LLC−51.4K (-5%)
- Two Sigma Investments−15.5K (-58%)
- State Street Corp−5.2K (-0%)
- U.S. Bancorp−76
Source: 13F-HR filings on SEC EDGAR (aggregated from 184 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ORGO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
| 4 | Mar 11, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 26, 2026 | - | Analysis | - |
| 8-K | Feb 23, 2026 | - | Analysis | - |
| 4 | Feb 20, 2026 | - | - | |
| 4 | Feb 20, 2026 | - | - | |
| 4 | Feb 20, 2026 | - | - | |
| 4 | Feb 20, 2026 | - | - | |
| 4 | Feb 20, 2026 | - | - | |
| 4 | Feb 20, 2026 | - | - | |
| 4 | Feb 20, 2026 | - | - | |
| 4 | Feb 20, 2026 | - | - | |
| 4 | Feb 20, 2026 | - | - | |
| 4 | Feb 20, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ORGO SEC filings: frequently asked questions
Which institutions hold ORGO stock?
As of June 30, 2026, the largest Organogenesis Holdings Inc. (ORGO) holders among the 13F filers tracked by SignalX were Morgan Stanley ($28.5 million), BlackRock ($17.6 million), Dimensional Fund Advisors ($7.4 million), AQR Capital Management ($7.3 million), Vanguard Capital Management LLC ($7.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ORGO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Organogenesis Holdings Inc. (ORGO) reported revenue of $564.2 million (up 17.0% from FY2024) and net income of $37.0 million. Diluted EPS was $0.15. The figures come from the XBRL data in the 10-K.
What did ORGO report in its latest 8-K?
Organogenesis Holdings Inc. (ORGO) filed an 8-K on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Fiscal Q2 2026 results covered quarter ended June 30, 2026.
What are the latest ORGO SEC filings?
Organogenesis Holdings Inc. (ORGO) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on April 24, 2026.
What is ORGO's SEC CIK number?
Organogenesis Holdings Inc. (ORGO)'s SEC Central Index Key (CIK) is 1661181. EDGAR lists every ORGO filing under that number.
Ask anything about ORGO
The research agent reads ORGO's filings, financials, insider trades and 13F holders, then answers with sources.